What Did Medicine Actually Know About Cannabis by 1999?
A plain-English summary of MED01 Part 1 (v1.0 — SIGNED OFF by Danny 2026-09-26; text = v0.2 after ChatGPT §M11 fidelity review)
Based on: the technical synthesis v1.0 (signed off 2026-09-26) and the 40-claim ledger. Simpler words, same uncertainty. Claim numbers in brackets lead to the technical version and its sources. Covers: research published 1960–1999, as the evidence stood then, found through our search cutoff of 20 September 2026. Not medical advice. This describes old studies. It does not say what cannabis does for you.
How we did this
Two AI researchers were given the same frozen instructions and worked separately. A verifier resolved the journal identifiers against the databases, checked the quantitative clinical claims against the available abstracts, re-ran the database searches, and independently opened official documents where they were accessible. Where the two disagreed, the checking decided. One researcher’s follow-up answers contained five more wrong reference numbers, each one paper away from the right one — all caught before anything was recorded. What survived is a 40-claim ledger. Some claims still have parts we’re waiting to confirm from original documents; those are marked below.
Was there really research back then?
Yes — a lot. Depending on how you search, PubMed lists between about 8,700 and 10,600 cannabis papers from those four decades [C001]. The shape is the same either way: a surge in the 1970s, a lull in the 1980s, a bigger peak in the 1990s. The United States produced the most, and its government agencies were prominent funders [C002].
The claim that “there was almost no research before legalization” doesn’t survive [C040]. What is true is that controlled trials of whether cannabis works for something were much smaller than the basic and pharmacological literature.
The discoveries — in the lab, not in patients
The big scientific story of the period happened in test tubes and animals. CBD’s structure was worked out in 1963 and THC’s in 1964; THC was first synthesised in 1965 [C004, C005]. That let scientists give exact doses of a known chemical for the first time.
Then, in 1988, researchers found a specific receptor for cannabinoids in rat brain tissue [C007]. The receptor’s gene was cloned in 1990 [C008], a molecule the body makes itself — anandamide — was found to fit it in 1992 [C009], a second receptor turned up in immune tissue in 1993 [C010], and a second body-made cannabinoid in 1995 [C011]. By 1999 scientists knew the body has its own cannabinoid signalling system. None of this was evidence that cannabis treats anything in people — it was evidence about how the chemistry works.
What was tested in people
The human trials were real, small, and specific to one product at a time.
Nausea from chemotherapy got the most attention. In 1975, 20 patients took THC pills or placebo: THC produced an anti-nausea/anti-vomiting response in 14 of 20 treatment courses, placebo in none of 22 [C012]. In 1979, nabilone — a synthetic relative of THC — beat the standard anti-nausea drug in 113 patients, though only 8% got complete relief and side effects were about twice as common [C014]. A later count found 23 such trials between 1975 and 1991, most with design weaknesses [C015]. Two cannabinoid drugs were approved during this period: nabilone in the UK in 1982 and the US in 1985; dronabinol (synthetic THC) in the US in 1985 [C023, C024].
Appetite in AIDS produced the largest trial: 139 patients in 1995. Dronabinol improved appetite (38% vs 8% on placebo). It did not significantly change weight [C021]. Those are two different results and it matters not to blur them.
Everything else was tiny. Ten cancer patients got some pain relief from 15–20 mg of THC, with heavy sedation — the researchers themselves called the effect “mild” [C016]. Ten asthma patients breathed easier for an hour after one puff of THC aerosol [C018]. Of fifteen people with hard-to-control epilepsy, 4 of 8 on added CBD were reported almost seizure-free and 3 more improved, against 1 of 8 on placebo [C019]. Nine patients had less muscle stiffness on 10 mg THC — but the examiner correctly guessed who’d had the drug 7 times out of 9, so the blinding was probably compromised [C020]. Smoking cannabis lowered eye pressure for a few hours [C017] — a measurement, not a glaucoma treatment.
Who this does not tell us about: these small studies do not establish effects for other populations, for modern products, or for long-term use.
The harms research was real too
A Swedish study followed 45,570 young men for 15 years; heavy cannabis users had six times the rate of schizophrenia. The authors described cannabis as an independent risk factor, but an observational study like this cannot by itself establish causation [C030]. Lung studies found short-term drops in function, airway inflammation in smokers, but no faster long-term decline of the kind tobacco causes — three separate findings [C031]. And by 1980 there was human evidence that very high doses of CBD slowed the breakdown of one sedative drug — a CBD–drug interaction [C032].
Was the era’s research “only about harms”? We found no dataset that supports a reliable percentage, so this evidence map cannot quantify the balance. Both kinds of research existed [C027].
The rules the research ran under
Cannabis was placed in the strictest US drug schedule in 1970, but research did not stop — the controlled US trials above were done after that [C026]. The early federal supply-programme details remain under document check [C025]. Researchers found reports of a US programme that supplied cannabis cigarettes to some seriously ill patients and was closed to new participants in 1992; the verifier has not yet been able to open the primary 1999 passage, and the often-repeated details (started 1978, 27 patients, 13–15 kept on) come from a memoir and second-hand accounts and are unresolved [C028]. A 1972 petition to loosen the rules went through a judge who recommended change in 1988; the DEA Administrator denied it in 1989, with a further denial and remand in 1992 [C029].
What the official reviews concluded
The World Health Organization reviewed the health evidence in 1997 [C034]. In 1998 the UK House of Lords said the evidence didn’t conclusively prove medical value, called urgently for trials in MS and pain, and recommended letting doctors prescribe cannabis; the UK Government refused until trials produced evidence [C035]. In 1999 the US Institute of Medicine concluded cannabinoid drugs showed potential for pain, nausea and appetite, called smoked marijuana a crude way to deliver a drug, and asked for trials of other forms [C036 — three readers report this; we have not yet opened the document ourselves].
What nobody had shown
This review identified no human study from the period showing cannabis treating cancer or slowing a brain disease. The evidence people point to is a 1975 mouse study (where CBD did nothing and THC slowed one tumour) and a 1998 experiment on rat neurons in a dish [C038]. A US government patent filed in 1999 rests on that dish experiment — a patent claims an idea, it doesn’t prove a treatment. We also identified no period human studies in children’s CBD epilepsy, inflammatory bowel disease, PTSD, or structured cannabis-for-opioid substitution [C039] — which is not the same as saying none exist.
So: what was known by 1999?
- Reasonably established, from small trials: THC pills and nabilone reduce chemotherapy nausea, with real side effects. Dronabinol improves appetite in AIDS — not weight. Cannabis and THC lower eye pressure briefly; aerosol THC opens airways briefly.
- Established in the lab, not in patients: the body’s own cannabinoid system.
- Suggested, not established: pain relief, muscle stiffness, CBD for epilepsy — each on nine to fifteen people.
- Claims for which this review did not identify supporting evidence: that cannabis treats cancer or brain disease; that “medical cannabis” had been proven across many illnesses; that official reports were suppressed.
The record is more interesting than either slogan about it. There was plenty of research. Much of it was narrower than later public claims sometimes imply.
What we may have missed
We searched the main medical databases and government archives, and re-checked everything. We did not search non-English journals well, most old papers were available only as summaries, and a few official documents are still being opened. Anything we say is missing means “not found by us,” not “doesn’t exist.”